Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The main purpose is to determine the pharmacokinetic (PK) profile, maximum concentration
(Cmax) and Area Under the Concentration Time Curve (AUC0-t) of Triferic iron administered
intraperitoneally in patients with chronic kidney disease on peritoneal dialysis (CKD-5 PD).
It is an open label, dose escalation study.